9 METERS BIOPHARMA, INC.

2021 Q4 Form 10-K Financial Statement

#000155198622000030 Filed on March 23, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.99M $46.99M $37.85M
YoY Change 24.16% 24.16% 724.62%
Cash & Equivalents $46.99M $46.99M $37.85M
Short-Term Investments
Other Short-Term Assets $2.992M $2.992M $1.080M
YoY Change 177.03% 177.03% 68.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $49.99M $49.99M $38.93M
YoY Change 28.41% 28.4% 645.3%
LONG-TERM ASSETS
Property, Plant & Equipment $16.09K $182.7K $11.19K
YoY Change 43.81% -20.56% -55.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.580K $5.580K $5.580K
YoY Change 0.0% -44.2% 0.0%
Total Long-Term Assets $188.3K $188.3K $231.5K
YoY Change -18.68% -18.13% 213.6%
TOTAL ASSETS
Total Short-Term Assets $49.99M $49.99M $38.93M
Total Long-Term Assets $188.3K $188.3K $231.5K
Total Assets $50.17M $50.17M $39.16M
YoY Change 28.13% 28.12% 639.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.434M $2.434M $1.488M
YoY Change 63.61% 63.39% -61.75%
Accrued Expenses $5.968M $6.023M $5.290M
YoY Change 12.81% 12.78% 11.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0% -99.69%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.457M $8.457M $6.848M
YoY Change 23.49% 23.46% -54.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $113.1K $113.1K $170.0K
YoY Change -33.45% -33.45%
Total Long-Term Liabilities $113.1K $113.1K $170.0K
YoY Change -33.45% -33.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.457M $8.457M $6.848M
Total Long-Term Liabilities $113.1K $113.1K $170.0K
Total Liabilities $8.570M $8.570M $7.016M
YoY Change 22.15% 22.08% -52.94%
SHAREHOLDERS EQUITY
Retained Earnings -$168.8M -$132.1M
YoY Change 27.85% 87.15%
Common Stock $25.82K $20.46K
YoY Change 26.2% 418.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.60M $41.60M $32.14M
YoY Change
Total Liabilities & Shareholders Equity $50.17M $50.17M $39.16M
YoY Change 28.13% 28.12% 639.28%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001551986
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37797
CY2021 dei Entity Registrant Name
EntityRegistrantName
9 METERS BIOPHARMA, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3948465
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
8480 Honeycutt Road
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 120
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Raleigh
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27615
CY2021 dei City Area Code
CityAreaCode
919
CY2021 dei Local Phone Number
LocalPhoneNumber
275-1933
CY2021 dei Security12b Title
Security12bTitle
Common Stock $0.0001 Par Value
CY2021 dei Trading Symbol
TradingSymbol
NMTR
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
274900000 USD
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
258235418 shares
CY2021 dei Auditor Firm
AuditorFirmId
199
CY2021 dei Auditor Name
AuditorName
Mayer Hoffman McCann P.C.
CY2021 dei Auditor Location
AuditorLocation
San Diego, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46993285 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37851388 USD
CY2021Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
0 USD
CY2020Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
75000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2991948 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1000587 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
49985233 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
38926975 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16094 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11191 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
166618 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
214767 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2021Q4 us-gaap Assets
Assets
50173525 USD
CY2020Q4 us-gaap Assets
Assets
39158513 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2434452 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1487948 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5967822 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5290181 USD
CY2021Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2020Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
14216 USD
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7000 USD
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
488 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54796 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
48629 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8457070 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6848462 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113142 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
167938 USD
CY2021Q4 us-gaap Liabilities
Liabilities
8570212 USD
CY2020Q4 us-gaap Liabilities
Liabilities
7016400 USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
258235418 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
258235418 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204629064 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
204629064 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
25824 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
20463 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
210418156 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
164182917 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168840667 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132061267 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41603313 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32142113 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50173525 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39158513 USD
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
21995291 USD
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10933023 USD
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5103753 USD
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
32266893 USD
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9662875 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10519955 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
60877758 USD
CY2021 nmtr Warrant Inducement Expense
WarrantInducementExpense
0 USD
CY2020 nmtr Warrant Inducement Expense
WarrantInducementExpense
7157887 USD
CY2021 us-gaap Operating Expenses
OperatingExpenses
36761919 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-36761919 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-60877758 USD
CY2021 us-gaap Interest Income Other
InterestIncomeOther
22707 USD
CY2020 us-gaap Interest Income Other
InterestIncomeOther
18992 USD
CY2021 us-gaap Interest Expense
InterestExpense
47188 USD
CY2020 us-gaap Interest Expense
InterestExpense
4046223 USD
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7000 USD
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
771000 USD
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2637500 USD
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17481 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-618731 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36779400 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-61496489 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-36779400 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-61496489 USD
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
243108526 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
243108526 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105642203 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105642203 shares
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4723000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-9614014 USD
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37168980 USD
CY2020 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
28754026 USD
CY2020 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
22560994 USD
CY2020 nmtr Stock Issued During Period Value Warrant Exchange
StockIssuedDuringPeriodValueWarrantExchange
690839 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6483998 USD
CY2020 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
2528648 USD
CY2020 nmtr Adjustments To Additional Paid In Capital Warrant Inducement Expense
AdjustmentsToAdditionalPaidInCapitalWarrantInducementExpense
6467048 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
4643007 USD
CY2020 nmtr Convertible Promissory Notes Beneficial Conversion Feature
ConvertiblePromissoryNotesBeneficialConversionFeature
2200072 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-61496489 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32142113 USD
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37218588 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2413000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2901123 USD
CY2021 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
9163174 USD
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
346961 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-36779400 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41603313 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-36779400 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-61496489 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2413000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4723000 USD
CY2021 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
0 USD
CY2020 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
307372 USD
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
43983 USD
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1519668 USD
CY2021 us-gaap Depreciation
Depreciation
7573 USD
CY2020 us-gaap Depreciation
Depreciation
18491 USD
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-39198 USD
CY2021 nmtr Convertible Promissory Notes Beneficial Conversion Feature
ConvertiblePromissoryNotesBeneficialConversionFeature
0 USD
CY2020 nmtr Convertible Promissory Notes Beneficial Conversion Feature
ConvertiblePromissoryNotesBeneficialConversionFeature
2200072 USD
CY2021 nmtr Noncash Research And Development In Process
NoncashResearchAndDevelopmentInProcess
2610588 USD
CY2020 nmtr Noncash Research And Development In Process
NoncashResearchAndDevelopmentInProcess
28754026 USD
CY2021 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-7000 USD
CY2020 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-771000 USD
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2637500 USD
CY2021 nmtr Warrant Inducement Expense
WarrantInducementExpense
0 USD
CY2020 nmtr Warrant Inducement Expense
WarrantInducementExpense
7157887 USD
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1991361 USD
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
445535 USD
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1054504 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2465074 USD
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3170326 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3685610 USD
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2021 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-488 USD
CY2020 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
488 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29478275 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19409786 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12476 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2543 USD
CY2021 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2493165 USD
CY2020 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3184454 USD
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
75000 USD
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2430641 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3186997 USD
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2500000 USD
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
23000 USD
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
58199 USD
CY2020 us-gaap Repayments Of Debt
RepaymentsOfDebt
2461472 USD
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34500000 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37147681 USD
CY2021 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
0 USD
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
22560994 USD
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
346961 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9163174 USD
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2528648 USD
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2901123 USD
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6397612 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41050813 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55855239 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9141897 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
33258456 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37851388 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4592932 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46993285 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37851388 USD
CY2021 us-gaap Interest Paid Net
InterestPaidNet
569 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
62912 USD
CY2021 nmtr Noncash Addition Of Derivative Liability
NoncashAdditionOfDerivativeLiability
0 USD
CY2020 nmtr Noncash Addition Of Derivative Liability
NoncashAdditionOfDerivativeLiability
370000 USD
CY2021 nmtr Noncash Addition Of Deferred Offering Costs
NoncashAdditionOfDeferredOfferingCosts
0 USD
CY2020 nmtr Noncash Addition Of Deferred Offering Costs
NoncashAdditionOfDeferredOfferingCosts
86386 USD
CY2020Q4 nmtr Saleof Stock Shelf Registration Maximum Equity Offering Price
SaleofStockShelfRegistrationMaximumEquityOfferingPrice
200000000 USD
CY2019Q4 nmtr Class Of Warrant Or Right Shares Issued Per Warrant Ratio
ClassOfWarrantOrRightSharesIssuedPerWarrantRatio
1.2
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12230418 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.10
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1200000 USD
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.10
CY2020Q2 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
22600000 USD
CY2020Q2 nmtr Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants Net
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsNet
19200000 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation of the derivative liability and warrant liabilities, valuation allowance for income tax assets, and management’s assessment of the Company’s ability to continue as a going concern. The Company considered the impact of the COVID-19 pandemic on its estimates and assumptions, and concluded there was not a material impact to its consolidated financial statements as of and for the year ended December 31, 2021. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</span></div>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. While cash held by financial institutions may at times exceed federally insured limits, management believes that no material credit or market risk exposure exists due to the high quality of the financial institutions. The Company has not experienced any losses on such accounts.</span></div>
CY2021 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1633295 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1111028 USD
CY2021Q4 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4228048 USD
CY2020Q4 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4042277 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106479 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
136876 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5967822 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5290181 USD
CY2020 nmtr Stock Issued During Period Shares Exerciseof Warrants
StockIssuedDuringPeriodSharesExerciseofWarrants
1847309 shares
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2600000 USD
CY2020Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
7000 USD
CY2019Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
3045500 USD
CY2021Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
0 USD
CY2020Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
7000 USD
CY2021 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
0 USD
CY2020 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
771000 USD
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
43900000 shares
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
56400000 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
43938829 shares
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
56368996 shares
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9200000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
85124 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
72648 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
69030 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
61457 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16094 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11191 USD
CY2020Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.65
CY2021Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.00
CY2020Q2 nmtr Number Of Amended And Restated License Agreements
NumberOfAmendedAndRestatedLicenseAgreements
2 licenseAgreement
CY2021Q3 nmtr Milestone Payment
MilestonePayment
500000 USD
CY2021 nmtr Accrued Milestone Fees
AccruedMilestoneFees
600000 USD
CY2020 nmtr Accrued Milestone Fees
AccruedMilestoneFees
2200000 USD
CY2021Q4 nmtr Capital Stock Authorized
CapitalStockAuthorized
560000000 shares
CY2021 nmtr Severance Provisions Annual Base Salary Period
SeveranceProvisionsAnnualBaseSalaryPeriod
P18M
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
600000 shares
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 nmtr Convertible Preferred Stock Beneficial Conversion Feature
ConvertiblePreferredStockBeneficialConversionFeature
3100000 USD
CY2020Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
12500000 USD
CY2020Q2 nmtr Preferred Stock Warrant Value
PreferredStockWarrantValue
7000000 USD
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
258235418 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204629064 shares
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
49417616 shares
CY2021 nmtr Severance Provisions Continuation Of Health Insurance Benefits Period
SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod
P12M
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
66167171 shares
CY2019Q4 nmtr Class Of Warrant Or Right Shares Issued Per Warrant Ratio
ClassOfWarrantOrRightSharesIssuedPerWarrantRatio
1.2
CY2020 nmtr Stock Issued During Period Shares Exerciseof Warrants
StockIssuedDuringPeriodSharesExerciseofWarrants
1847309 shares
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12230418 shares
CY2020Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1200000 USD
CY2021Q4 nmtr Number Of Stock Option Plans
NumberOfStockOptionPlans
2 equity-basedIncentivePlan
CY2021Q2 nmtr Sale Of Stock Extended Option Period
SaleOfStockExtendedOptionPeriod
P12M
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2413000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4723000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18656500 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13798700 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
5134700 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
4587100 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2534600 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1358200 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3647100 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3864900 USD
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3096800 USD
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3139400 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
371200 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
88500 USD
CY2021Q4 nmtr Deferred Tax Assets Legal Fees
DeferredTaxAssetsLegalFees
0 USD
CY2020Q4 nmtr Deferred Tax Assets Legal Fees
DeferredTaxAssetsLegalFees
40200 USD
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
20500 USD
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
204800 USD
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
5900 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
6900 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33467300 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27088700 USD
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6265600 USD
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7240100 USD
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7726800 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-12914300 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-27900 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.001
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-661300 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.011
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
4500 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
1337100 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.022
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-6425000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.104
CY2021 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1176500 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.032
CY2020 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
634400 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.010
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
2400 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-562600 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.009
CY2021 nmtr Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Amount
EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalAmount
1764100 USD
CY2021 nmtr Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Percent
EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalPercent
-0.048
CY2020 nmtr Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Amount
EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalAmount
-1400 USD
CY2020 nmtr Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Percent
EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalPercent
0
CY2021 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
894600 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.025
CY2020 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
107400 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.001
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6265600 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.170
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6904500 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.113
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
3551900 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
85170300 USD
CY2021Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
11000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2534600 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233206 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
233206 USD
CY2021 us-gaap Severance Costs1
SeveranceCosts1
400000 USD
CY2020 us-gaap Severance Costs1
SeveranceCosts1
800000 USD
CY2021 nmtr Severance Costs Equal Installment Period
SeveranceCostsEqualInstallmentPeriod
P12M
CY2021Q4 nmtr Deferred Compensation Liability Severance Accrual
DeferredCompensationLiabilitySeveranceAccrual
400000 USD
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 nmtr Operating Lease Annual Rental Payments
OperatingLeaseAnnualRentalPayments
72000 USD
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 USD
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 USD
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
71520 USD
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
64800 USD
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
100000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
72000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
72000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
54000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
198000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
30062 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
167938 USD

Files In Submission

Name View Source Status
0001551986-22-000030-index-headers.html Edgar Link pending
0001551986-22-000030-index.html Edgar Link pending
0001551986-22-000030.txt Edgar Link pending
0001551986-22-000030-xbrl.zip Edgar Link pending
ex-10171amendedemploymenta.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nmtr-20211231.htm Edgar Link pending
nmtr-20211231.xsd Edgar Link pending
nmtr-20211231_cal.xml Edgar Link unprocessable
nmtr-20211231_def.xml Edgar Link unprocessable
nmtr-20211231_g1.jpg Edgar Link pending
nmtr-20211231_g10.jpg Edgar Link pending
nmtr-20211231_g11.jpg Edgar Link pending
nmtr-20211231_g12.jpg Edgar Link pending
nmtr-20211231_g13.jpg Edgar Link pending
nmtr-20211231_g14.jpg Edgar Link pending
nmtr-20211231_g15.jpg Edgar Link pending
nmtr-20211231_g16.jpg Edgar Link pending
nmtr-20211231_g2.jpg Edgar Link pending
nmtr-20211231_g3.jpg Edgar Link pending
nmtr-20211231_g4.jpg Edgar Link pending
nmtr-20211231_g5.jpg Edgar Link pending
nmtr-20211231_g6.jpg Edgar Link pending
nmtr-20211231_g7.jpg Edgar Link pending
nmtr-20211231_g8.jpg Edgar Link pending
nmtr-20211231_g9.jpg Edgar Link pending
nmtr-20211231_htm.xml Edgar Link completed
nmtr-20211231_lab.xml Edgar Link unprocessable
nmtr-20211231_pre.xml Edgar Link unprocessable
nmtrex-3112021.htm Edgar Link pending
nmtrex23-12021consent.htm Edgar Link pending
nmtrex31-22021.htm Edgar Link pending
nmtrex32-12021.htm Edgar Link pending
nmtrex32-22021.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending